RET-IN-22
RET-IN-22 (compound 17b) is a potent, selective and orally active RET inhibitor with an IC50 of 20.9 nM and 18.3 nM for wild-type RET and RET-V804M, respectively. RET-IN-22 shows highly selective profile to most kinases, especially to EGFR and VEGFR2. RET-IN-22 has anticancer effects[1].
Product Specifications
CAS Number
2918281-79-3
UNSPSC
12352005
Target
RET
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ret-in-22.html
Solubility
10 mM in DMSO
Smiles
O=C(NC1=CC=C(C2=NNC(C3=CC=C(OCCN4CCOCC4)C=C3)=C2)C=C1)NC5=NOC(C(C)(C(F)(F)F)C)=C5
Molecular Formula
C29H31F3N6O4
Molecular Weight
584.59
References & Citations
[1]Kaifu Wu, et al. Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors. Eur J Med Chem. 2023 May 5;251:115237.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cytokeratin 6A (KRT6A) (Basal Cell Marker) (rKRT6A/2100), CF405S conjugate, 0.1mg/mL
TIMP1 (Colorectal and Lymph Node Metastasis Marker) (TIMP1/1944R), CF640R conjugate, 0.1mg/mL
